Insulin analogues in type 1 diabetes mellitus: getting better all the time
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Insulin analogues in type 1 diabetes mellitus: getting better all the time
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 13, Issue 7, Pages 385-399
Publisher
Springer Nature
Online
2017-04-21
DOI
10.1038/nrendo.2017.39
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia
- (2016) Ulrik Pedersen-Bjergaard et al. CURRENT MEDICAL RESEARCH AND OPINION
- 8. Pharmacologic Approaches to Glycemic Treatment
- (2016) DIABETES CARE
- Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
- (2016) L. L. Ilag et al. DIABETES OBESITY & METABOLISM
- Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
- (2016) Helle Linnebjerg et al. DIABETES OBESITY & METABOLISM
- Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
- (2016) K. Cusi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
- (2016) I. Hadjiyianni et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
- (2016) R. M. Bergenstal et al. DIABETES OBESITY & METABOLISM
- A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1
- (2016) S. Garg et al. DIABETES OBESITY & METABOLISM
- Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial
- (2016) Tim Heise et al. DIABETES OBESITY & METABOLISM
- Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)
- (2016) Munehide Matsuhisa et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1)
- (2016) I. B. Hirsch et al. DIABETIC MEDICINE
- A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
- (2016) Tim Heise et al. DRUGS & AGING
- Pursuit of a perfect insulin
- (2016) Alexander N. Zaykov et al. NATURE REVIEWS DRUG DISCOVERY
- Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study
- (2016) S. Galasso et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus
- (2016) Asrul Akmal Shafie et al. PHARMACOECONOMICS
- How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
- (2016) Araceli Muñoz-Garach et al. Diabetes Therapy
- How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
- (2016) Araceli Muñoz-Garach et al. Diabetes Therapy
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
- (2015) Philip D. Home et al. DIABETES CARE
- Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies
- (2015) Helle Linnebjerg et al. DIABETES CARE
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- (2015) John B. Buse et al. DIABETES CARE
- Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes
- (2015) R. Herring et al. DIABETES OBESITY & METABOLISM
- Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
- (2015) R. H. A. Becker et al. DIABETES OBESITY & METABOLISM
- Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
- (2015) T. Heise et al. DIABETES OBESITY & METABOLISM
- Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
- (2015) Paolo Pozzilli et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
- (2015) S. Heller et al. DIABETIC MEDICINE
- Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
- (2015) Tim Heise et al. Expert Opinion on Drug Metabolism & Toxicology
- Moving toward the ideal insulin for insulin pumps
- (2015) Eda Cengiz et al. Expert Review of Medical Devices
- Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
- (2015) Nandu Thalange et al. PEDIATRIC DIABETES
- Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates
- (2015) Danny Hung-Chieh Chou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus
- (2015) Stephen Atkin et al. Therapeutic Advances in Chronic Disease
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
- (2014) Hanne Haahr et al. CLINICAL PHARMACOKINETICS
- Inhaled Insulin: A Breath of Fresh Air? A Review of Inhaled Insulin
- (2014) Tricia Santos Cavaiola et al. CLINICAL THERAPEUTICS
- Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
- (2014) Robert R. Henry et al. DIABETES CARE
- Insulin Pens and New Ways of Insulin Delivery
- (2014) Lutz Heinemann Diabetes Technology & Therapeutics
- Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects
- (2014) Vikram P. Sinha et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cell factories for insulin production
- (2014) Nabih A Baeshen et al. Microbial Cell Factories
- Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
- (2014) A. C. Tricco et al. BMJ-British Medical Journal
- Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial
- (2014) Ulrik Pedersen-Bjergaard et al. Lancet Diabetes & Endocrinology
- Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
- (2014) Tim Heise et al. Diabetes Therapy
- A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec
- (2013) Stefan Korsatko et al. CLINICAL DRUG INVESTIGATION
- Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production
- (2013) Yan Wang et al. DIABETES
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
- (2013) David M. Nathan et al. DIABETES CARE
- Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes
- (2013) G. Koehler et al. DIABETES OBESITY & METABOLISM
- PEGylated insulin Lispro, (LY2605541)-a new basal insulin analogue
- (2013) T. M. Caparrotta et al. DIABETES OBESITY & METABOLISM
- A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review
- (2013) B. M. Frier et al. DIABETES OBESITY & METABOLISM
- Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences
- (2013) Tim Heise et al. Endocrine Practice
- Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
- (2013) Ian Blumer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
- (2013) Chantal Mathieu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Type 1 diabetes
- (2013) Mark A Atkinson et al. LANCET
- Design of Non-Standard Insulin Analogs for the Treatment of Diabetes Mellitus
- (2012) V. Pandyarajan et al. Current Diabetes Reports
- Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes
- (2012) E. R. Mathiesen et al. DIABETES CARE
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences
- (2012) P. D. Home DIABETES OBESITY & METABOLISM
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis
- (2011) Erika Pollex et al. ANNALS OF PHARMACOTHERAPY
- A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes: A randomized, controlled trial
- (2011) T. Heise et al. DIABETES CARE
- Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
- (2011) A. de la Pena et al. DIABETES CARE
- Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study
- (2011) P. Lucidi et al. DIABETES CARE
- Pharmacokinetics and Pharmacodynamics of Basal Insulins
- (2011) Francesca Porcellati et al. Diabetes Technology & Therapeutics
- Glycemic Control and Pregnancy Outcomes in Women with Type 1 Diabetes Mellitus Using Lispro Versus Regular Insulin: A Systematic Review and Meta-Analysis
- (2011) Cintia González Blanco et al. Diabetes Technology & Therapeutics
- Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus
- (2011) Nandu Thalange et al. PEDIATRIC DIABETES
- Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes
- (2010) G. B. Bolli et al. DIABETES OBESITY & METABOLISM
- Analysis of 24-Hour Glycemic Excursions in Patients with Type 1 Diabetes by Using Continuous Glucose Monitoring
- (2010) Kentaro Taki et al. Diabetes Technology & Therapeutics
- Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy Volunteers
- (2010) S. Arnolds et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial
- (2009) Simon Heller et al. CLINICAL THERAPEUTICS
- Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal–bolus regimens: insights from the PREDICTIVE study
- (2009) Kjeld Hermansen et al. CURRENT MEDICAL RESEARCH AND OPINION
- A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period
- (2008) Stephen Luzio et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Better Postprandial Glucose Stability During Continuous Subcutaneous Infusion with Insulin Aspart Compared with Insulin Lispro in Patients with Type 1 Diabetes
- (2008) Paolo Di Bartolo et al. Diabetes Technology & Therapeutics
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search